This analysis evaluates the company’s strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the company’s historical and forecast financial performance. The report also gives an in-depth analysis of the company’s key prescription pharmaceutical product, and provides a forecast sales performance for this drug.
Features and benefits
* Gain insight into Ironwood Pharmaceuticals' strategic outlook
* Analyze company sales forecasts by product
Highlights
Linaclotide is Ironwood Pharmaceuticals' most advanced product candidate. This drug is an orally administered guanylate cyclase type-C (GC-C) agonist for irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC). It is the main driver for the company.
No. of Pages: 32
Price: Single User License: US$ 5700 Corporate User License: US$14250
Table of Contents
ABOUT THIS REPORT
PharmaVitae Explorer database
Chapter structure
Sales and product analysis
Financial analysis
Data sourcing
Analyst consensus
EXECUTIVE SUMMARY
Company introduction
Recent developments
Corporate relationships
Strategic overview
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
SALES AND PRODUCT ANALYSIS
Sales overview
Product analysis
Product sales
IBS-C and CC background
Linaclotide
Key competitors
Clinical trials
Commercial impact of trial results
Key forecasting assumptions
Early-stage products
IW-6118
MD-0727
IW-1221
Features and benefits
* Gain insight into Ironwood Pharmaceuticals' strategic outlook
* Analyze company sales forecasts by product
Highlights
Linaclotide is Ironwood Pharmaceuticals' most advanced product candidate. This drug is an orally administered guanylate cyclase type-C (GC-C) agonist for irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC). It is the main driver for the company.
Ironwood Pharmaceuticals Market
Published: April 2012No. of Pages: 32
Price: Single User License: US$ 5700 Corporate User License: US$14250
Table of Contents
ABOUT THIS REPORT
PharmaVitae Explorer database
Chapter structure
Sales and product analysis
Financial analysis
Data sourcing
Analyst consensus
EXECUTIVE SUMMARY
Company introduction
Recent developments
Corporate relationships
Strategic overview
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
SALES AND PRODUCT ANALYSIS
Sales overview
Product analysis
Product sales
IBS-C and CC background
Linaclotide
Key competitors
Clinical trials
Commercial impact of trial results
Key forecasting assumptions
Early-stage products
IW-6118
MD-0727
IW-1221
